Canada markets open in 5 hours 34 minutes

Satellos Bioscience Inc. (MSCL.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
0.3900-0.0100 (-2.50%)
At close: 03:52PM EST
Full screen
Previous Close0.4000
Open0.4050
Bid0.3800 x N/A
Ask0.3900 x N/A
Day's Range0.3900 - 0.4250
52 Week Range0.2200 - 1.2000
Volume161,989
Avg. Volume39,291
Market Cap16.301M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Newsfile

    Satellos Bioscience Announces Significant Increase in Muscle Size and Function in Duchenne Muscular Dystrophy Disease Model

    - 40% increase in muscle size compared to control mice - 25% increase in muscle force, approaching levels seen in normal miceToronto, Ontario--(Newsfile Corp. - February 6, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (OTCQB: MSCLF) ("Satellos" or the "Company"), a drug discovery company developing small molecule therapeutics to regenerate muscle as a new approach to treating disease conditions from muscular dystrophy to aging, is pleased to announce results from multiple preclinical studies in

  • Newsfile

    Satellos Bioscience Announces Development Candidate

    - SAT-3153 Designated for pre-IND Studies - Toronto, Ontario--(Newsfile Corp. - January 3, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (OTCQB: MSCLF) ("Satellos" or the "Company"), a drug discovery company developing small molecule therapeutics to regenerate muscle as a new approach to treating disease conditions from muscular dystrophy to aging, is pleased to announce that it has designated SAT-3153 for development towards an IND filing."We are thrilled to be in a position to move SAT-3153 ..

  • Newsfile

    Satellos Bioscience Announces Q3 2022 Financial Results and Operational Highlights

    Toronto, Ontario--(Newsfile Corp. - November 23, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Corporation"), a drug discovery company developing therapeutics to regenerate muscle as a new approach to treating disease conditions from muscular dystrophy to aging, announced today its financial results and operational highlights for the quarter ending September 30, 2022. The Company's interim condensed consolidated financial statements for the quarter ended September 30, 2022, a